Symbol
| KLF5
| contributors: mct/pgu - updated : 03-03-2017
|
HGNC name
| Kruppel-like factor 5 (intestinal)
|
HGNC id
| 6349
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
| deletion
|  
|  
|
frequent hemizygous deletion or loss of expression in breast cancer | tumoral
|  
|  
| --low
|  
|
an LOH and loss of function in prostate cancer | tumoral
|  
|  
| --low
|  
|
in intestinal tumors | tumoral
|  
|  
|  
|  
|
silenced by hypermethylation in acute myeloid leukemia  | tumoral
|  
|  
| --low
|  
|
was lost concurrently with NOTCH1 in squamous cell cancers  | |
Variant & Polymorphism
|
| |
Candidate gene
| may be a tumor suppressor gene in prostate cancer |
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | reproductive | breast |  |
FBXW7 tumor suppressor targeting KLF5 for ubiquitin-mediated degradation and suppression of breast cell proliferation, is a therapeutic target for breast cancer and other cancers | cardiovascular | | |  |
potential diagnostic biomarker and therapeutic target for cardiovascular diseases | cancer | digestive | oesophagus |  |
KLF5 may be a useful diagnostic and therapeutic target in esophageal squamous carcinomas and possibly more generally in other cancers associated with TP53 loss of function
|
| | |
| Klf5 knockout mice, homozygous mutant died before embryonic day 8.5 | |
Klf5 +/- mice showed diminished levels of arterial wall thickening angiogenesis, cardiac hypertrophy and intestinal fibrosis in response to external stress |
|
Klf5 null mice were markedly deficient in white adipose tissue development |